GovChime
Notice ID: e648d77020744fddbd40db916d467d67Combined Synopsis/Solicitation

TPSU Cepheid 4Plex and COVID-19 Testing Kits

Archived on August 27, 2022. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
12:00 PM UTC−06:00
Posted
July 28, 2022
Notice type
Combined Synopsis/Solicitation
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Department of Health and Human ServicesINDIAN HEALTH SERVICE

Notice details

Office
ALBUQUERQUE AREA INDIAN HEALTH SVC
Place of performance
76200, NM, 87571
Last updated
Dec 4, 2025

Identifiers

Solicitation number
75H70722Q00075
Notice ID
e648d77020744fddbd40db916d467d67

Description

The Albuquerque Area Indian Health Service (AAIHS) has a requirement for the following supply/service: Cepheid Testing Supplies Prospective Offerors are invited to submit proposals in reference to solicitation no. 75H70722Q00075. The solicitation package is comprised of all information including the estimated requirements, scope of work, and applicable attachments. QUESTIONS In accordance with FAR 15.201 Exchanges with Industry before receipt of proposals, please refer to solicitation #(i.e. 18-242-SOL-XXXX) when requesting information regarding the solicitation via e-mail to eric.wright@ihs.gov, facsimile: (505) 256-6848 or phone: (505) 256-6752. The last day to submit any questions will be 5 business days at 12 pm prior to the solicitation close date. The Government anticipates in issuing a single award. Prospective Offerors are required to submit quotes/proposals by email to: eric.wright@ihs.gov To be eligible for contract award, vendor must be registered in the System for Award Management (SAM) and must also complete Representations and Certifications at http://www.sam.gov, per FAR 52.204-7. All payments by the Government under any associated order shall be made by electronic funds transfer (EFT), per FAR 52.232-33. In accordance with HHSAR 352.232-71 Electronic Submission of Invoice Payment, contractors will submit payment requests electronically using the Department of Treasury Invoice Processing Platform (IPP) or successor system. Information regarding IPP, including IPP Customer Support contact information, is available at www.ipp.gov. Proposals will be accepted at 12:00 pm MST on August 12, 2022 Late proposals will not be accepted unless post marked prior to the time and date of the due date. 1. (EQUIPMENT ONLY) Equipment Condition - New Equipment ONLY; NO remanufactured or "gray market" items. All items must be covered by the manufacturer's warranty. 2. Offer Period - Bid MUST be good for 30 calendar days after close of solicitation. 3. (EQUIPMENT ONLY) Shipping Condition - Shipping must be free on board (FOB) destination CONUS (Continental U.S.), which means that the seller must deliver the goods on its conveyance at the destination specified by the buyer, and the seller is responsible for the cost of shipping and risk of loss prior to actual delivery at the specified destination. 4. SAM Requirement - This solicitation requires registration with the System for Award Management (SAM) prior to award, pursuant to applicable regulations and guidelines. Registration information can be found at www.sam.gov. 5. Commercial Items Terms and Conditions - The selected Offeror must comply with the following commercial item terms and conditions, which are incorporated herein by reference: FAR 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition; FAR 52.212-3, Offeror Representations and Certifications - Commercial Items - the selected offeror must submit a completed copy of the listed representations and certifications; FAR 52.212-4, Contract Terms and Conditions - Commercial Items; FAR 52.212-5, Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Items, paragraph (a) and the following clauses in paragraph (b): 52.222-21, 52.222-26, 52.222-35, 52.222-36, 52.222-37, 52.225-13, 52.232-34. The full text of the referenced FAR clauses may be accessed electronically at https://www.acquisition.gov/far/. 6. Terms and Conditions - This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 Streamlined Procedures for Evaluation and Solicitation for Commercial Items, as supplemented with additional information included in this notice. This procurement is being conducted under FAR Part 13, Simplified Acquisition Procedures. 52.204-7, 52.212-3, 52.213-4, 52.222-36.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75H70722Q00075
  1. Combined Synopsis
  1. Combined SynopsisCurrentJul 28, 2022

    TPSU Cepheid 4Plex and COVID-19 Testing Kits

    Notice e648d77020744fddbd40db916d467d67 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This innovation from scientists at Los Alamos National Laboratory is a significant improvement on a gold standard protein purification method that gently captures and releases antibodies using mild pH changes, making antibody purification safer, more efficient, and less damaging. The Challenge: Purifying antibodies — vital tools in medicine and research — typically relies on a protein called Protein G that latches onto them. However, getting the antibodies back off this molecular “magnet” requires very acidic conditions, which can damage both the antibodies and Protein G itself. This harsh process risks ruining expensive materials and reducing the effectiveness of critical therapies and tests. Problems Solved: Researchers engineered a pH-switchable version of Protein G that uses gentle changes in acidity (pH) to control when it releases antibodies, it now binds antibodies at a mildly acidic pH and releases at a mildly basic pH — eliminating the need for harsh chemicals. This innovation protects sensitive proteins, improves efficiency, lowers costs, and opens the door for safer, greener, and more effective antibody purification in both labs and industry. Key Advantages: Gentle elution conditions: Antibodies are released at a mild pH (~8.2) instead of harsh acidic conditions (~2.7), reducing damage to both the antibodies and the protein itself. Improved antibody stability and yield: Preserving antibody structure increases reliability and effectiveness, which is especially critical for therapeutic and diagnostic use. Switchable binding mechanism: pH-sensitive histidine residues allow for a controlled "on/off" switch based on pH, improving process control and reproducibility. Cost-effective and scalable: Reduces loss of expensive antibodies and minimizes the need for post-purification repair or replacement, saving money in industrial applications. Market Applications: Biopharmaceuticals Life Sciences Research Bioprocessing and Manufacturing Tools Veterinary and Agricultural Biotech Development Status: TRL 4 US Provisional / Patent No. 10,954,275 LA-UR-25-29451 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search
-Special Notice12/05/2025
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
-Combined Synopsis11/05/2026
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers.
-Combined Synopsis11/18/2026
See attached Sources Sought Notice.
-Market Research10/28/2026
Amendment 5 is being issued to re-open the solicitation and proceed with source selection activities. Reinstate Jennifer Gartzke as the point of contact. The attached SF30 contains additional information.
-Solicitation02/15/2026

Additional Details

Solicitation Number

75H70722Q00075

Archive Date

Aug 27, 2022

Office Address

ALBUQUERQUE, NM, 87110